FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2074664983> ?p ?o ?g. }

• W2074664983 endingPage "1092" @default.
• W2074664983 startingPage "1081" @default.
• W2074664983 abstract "Interferon-activated monocytes are known to exert cytocidal activity against tumor cells in vitro. Here, we have examined whether a combination of IFN-α2a and IFN-γ and human monocytes mediate significant antitumor effects against human ovarian and melanoma tumor xenografts in mouse models. OVCAR-3 tumors were treated i.t. with monocytes alone, IFN-α2a and IFN-γ alone or combination of all three on day 0, 15 or 30 post-tumor implantation. Mice receiving combination therapy beginning day 15 showed significantly reduced tumor growth and prolonged survival including complete regression in 40% mice. Tumor volumes measured on day 80 in mice receiving combination therapy (206 mm3) were significantly smaller than those of mice receiving the IFNs alone (1,041 mm3), monocytes alone (1,111 mm3) or untreated controls (1,728 mm3). Similarly, combination therapy with monocytes and IFNs of much larger tumor also inhibited OVCAR-3 tumor growth. Immunohistochemistry studies showed a large number of activated macrophages (CD31+/CD68+) infiltrating into OVCAR-3 tumors and higher densities of IL-12, IP10 and NOS2, markers of M1 (classical) macrophages in tumors treated with combination therapy compared to the controls. Interestingly, IFNs-activated macrophages induced apoptosis of OVCAR-3 tumor cells as monocytes alone or IFNs alone did not mediate significant apoptosis. Similar antitumor activity was observed in the LOX melanoma mouse model, but not as profound as seen with the OVCAR-3 tumors. Administration of either mixture of monocytes and IFN-α2a or monocytes and IFN-γ did not inhibit Lox melanoma growth; however, a significant inhibition was observed when tumors were treated with a mixture of monocytes, IFN-α2a and IFN-γ. These results indicate that monocytes and both IFN-α2a and IFN-γ may be required to mediate profound antitumor effect against human ovarian and melanoma tumors in mouse models." @default.
• W2074664983 created "2016-06-24" @default.
• W2074664983 creator A5025528747 @default.
• W2074664983 creator A5046285455 @default.
• W2074664983 creator A5058608433 @default.
• W2074664983 creator A5059575766 @default.
• W2074664983 creator A5067972591 @default.
• W2074664983 creator A5077877614 @default.
• W2074664983 creator A5080821313 @default.
• W2074664983 creator A5081192007 @default.
• W2074664983 creator A5081807758 @default.
• W2074664983 date "2011-12-13" @default.
• W2074664983 modified "2023-09-24" @default.
• W2074664983 title "Potent antitumor effects of combination therapy with IFNs and monocytes in mouse models of established human ovarian and melanoma tumors" @default.
• W2074664983 cites W1815665069 @default.
• W2074664983 cites W1969174874 @default.
• W2074664983 cites W1975720774 @default.
• W2074664983 cites W1981885332 @default.
• W2074664983 cites W1983279602 @default.
• W2074664983 cites W1985024301 @default.
• W2074664983 cites W1985284776 @default.
• W2074664983 cites W2001997117 @default.
• W2074664983 cites W2006471464 @default.
• W2074664983 cites W2010190974 @default.
• W2074664983 cites W2012451630 @default.
• W2074664983 cites W2015141049 @default.
• W2074664983 cites W2017449430 @default.
• W2074664983 cites W2020744745 @default.
• W2074664983 cites W2025066885 @default.
• W2074664983 cites W203004974 @default.
• W2074664983 cites W2038689279 @default.
• W2074664983 cites W2052313621 @default.
• W2074664983 cites W2053505020 @default.
• W2074664983 cites W2053990081 @default.
• W2074664983 cites W2054472394 @default.
• W2074664983 cites W2062771633 @default.
• W2074664983 cites W2066290853 @default.
• W2074664983 cites W2068850623 @default.
• W2074664983 cites W2070473637 @default.
• W2074664983 cites W2074424194 @default.
• W2074664983 cites W2079224095 @default.
• W2074664983 cites W2090203203 @default.
• W2074664983 cites W2092159426 @default.
• W2074664983 cites W2092386544 @default.
• W2074664983 cites W2095677734 @default.
• W2074664983 cites W2096358091 @default.
• W2074664983 cites W2105899429 @default.
• W2074664983 cites W2112057120 @default.
• W2074664983 cites W2118205675 @default.
• W2074664983 cites W2135113513 @default.
• W2074664983 cites W2141146648 @default.
• W2074664983 cites W2143340901 @default.
• W2074664983 cites W2145485696 @default.
• W2074664983 cites W2149200346 @default.
• W2074664983 cites W2151948277 @default.
• W2074664983 cites W2157962067 @default.
• W2074664983 cites W2394497789 @default.
• W2074664983 cites W4247277860 @default.
• W2074664983 cites W4250722439 @default.
• W2074664983 doi "https://doi.org/10.1007/s00262-011-1152-x" @default.
• W2074664983 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3467013" @default.
• W2074664983 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22159517" @default.
• W2074664983 hasPublicationYear "2011" @default.
• W2074664983 type Work @default.
• W2074664983 sameAs 2074664983 @default.
• W2074664983 citedByCount "21" @default.
• W2074664983 countsByYear W20746649832012 @default.
• W2074664983 countsByYear W20746649832013 @default.
• W2074664983 countsByYear W20746649832014 @default.
• W2074664983 countsByYear W20746649832015 @default.
• W2074664983 countsByYear W20746649832016 @default.
• W2074664983 countsByYear W20746649832017 @default.
• W2074664983 countsByYear W20746649832018 @default.
• W2074664983 countsByYear W20746649832019 @default.
• W2074664983 countsByYear W20746649832020 @default.
• W2074664983 countsByYear W20746649832021 @default.
• W2074664983 countsByYear W20746649832022 @default.
• W2074664983 crossrefType "journal-article" @default.
• W2074664983 hasAuthorship W2074664983A5025528747 @default.
• W2074664983 hasAuthorship W2074664983A5046285455 @default.
• W2074664983 hasAuthorship W2074664983A5058608433 @default.
• W2074664983 hasAuthorship W2074664983A5059575766 @default.
• W2074664983 hasAuthorship W2074664983A5067972591 @default.
• W2074664983 hasAuthorship W2074664983A5077877614 @default.
• W2074664983 hasAuthorship W2074664983A5080821313 @default.
• W2074664983 hasAuthorship W2074664983A5081192007 @default.
• W2074664983 hasAuthorship W2074664983A5081807758 @default.
• W2074664983 hasBestOaLocation W20746649832 @default.
• W2074664983 hasConcept C126322002 @default.
• W2074664983 hasConcept C190283241 @default.
• W2074664983 hasConcept C202751555 @default.
• W2074664983 hasConcept C203014093 @default.
• W2074664983 hasConcept C204232928 @default.
• W2074664983 hasConcept C2776460901 @default.
• W2074664983 hasConcept C2776999253 @default.
• W2074664983 hasConcept C2777658100 @default.
• W2074664983 hasConcept C2778939058 @default.
• W2074664983 hasConcept C2780394083 @default.

• next